Kongressthemen
Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron and more.
https://go.evvnt.com/727512-2?pid=4832
Herr Customer Service
KategorienAllgemeinmedizin
